Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...
China NMPA grants breakthrough therapy designation for Innovent’s PD-1/IL-2a-bias bispecific antibody fusion protein, IBI363 in melanoma: San Francisco, US Tuesday, April 1, 202 ...
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.
Key Highlights: <li /> Global first immuno + anti-vascular bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC.
On April 1, several elections will take place across Vermilion County, including those for alderperson, mayor of Hoopeston, ...
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
Advancement of AbbVie Inc. and OSE Immunotherapeutics strategic partnership to develop ABBV-230: in April 2024, the Hart-Scott-Rodino waiting period expired enabling teams to commence work around the ...